Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Camcevi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlueCross BlueShield of TennesseePolicy ID_CHS_47632026_0926

    Leuprolide Mesylate (Camcevi ETM™; Camcevi Kit)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_47632026_0926 alerts

    Get alerted when Policy ID_CHS_47632026_0926 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for Camcevi (leuprolide mesylate) for adult advanced prostate cancer and specified salivary gland tumors for BlueCross BlueShield of Tennessee members.

    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyLeuprolide Mesylate (Camcevi ETM™; Camcevi Kit)
    Policy CodePolicy ID_CHS_47632026_0926
    Change TypeNo material clinical or coverage changes
    Effective DateDec 1, 202612d
    Next Review DateN/A
    Key ActionSubmit androgen receptor (AR)-positive test results when applicable to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    2Covered use categories
    AR-positiveRequired tumor status
    Not covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Other indications

    Coverage Criteria

    Prostate Cancer Initial Therapy

    Authorization of 12 months may be granted when the following criterion is met:

    Prostate cancer indication

    • Treatment of prostate cancer

    Salivary Gland Tumor Initial Therapy

    Authorization of 12 months may be granted when all of the following criteria are met:

    Salivary gland tumor indication

    • Disease status

      • The tumor is recurrent
      • The tumor is unresectable
      • The tumor is metastatic
    • Tumor status

      • The tumor is androgen receptor positiveAR-positive
    • Regimen

      • Treatment is administered as a single agent
      • Treatment is administered in combination with abiraterone and prednisone

    Prostate Cancer Continuation Therapy

    Authorization of 12 months may be granted for reauthorization when all of the following criteria are met:

    Prostate cancer continuation therapy

    • Clinical benefit

      • The member is experiencing clinical benefit to therapySerum testosterone <50 ng/dL (example of clinical benefit)
    • Safety

      • The member has not experienced unacceptable toxicity

    Salivary Gland Tumor Continuation Therapy

    Authorization of 12 months may be granted for reauthorization when all of the following criteria are met:

    Salivary gland tumor continuation therapy

    • Safety

      • There is no evidence of unacceptable toxicity while on the current regimen
    • Disease control

      • There is no evidence of disease progression while on the current regimenNo disease progression

    Indications outside the listed FDA-approved and compendial uses are considered experimental/investigational and not medically necessary.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization and Supporting Documentation

    Prior authorization is required where applicable. Covered indications include FDA-approved and compendial uses only when all approval criteria are met and the member has no exclusions to the prescribed therapy. Submit the supporting documentation needed for review.

    • Confirm the requested use is covered and that all applicable approval criteria are satisfied.
    • Include clinical documentation supporting the requested indication and eligibility.
    Documentation Required

    AR-Positive Test Results Required

    Submit laboratory or other test results confirming androgen receptor (AR)-positive status when applicable to the requested treatment.

    • AR-positive test results are required to initiate prior authorization review where applicable.

    Policy Background

    Camcevi (leuprolide mesylate) is covered for adults with advanced prostate cancer and for specified compendial uses, including prostate cancer and salivary gland tumors. For salivary gland tumors, coverage applies to recurrent, unresectable, or metastatic androgen receptor-positive disease; treatment may be given as monotherapy or with abiraterone and prednisone.

    Initial Therapy

    Prostate Cancer

    Authorization of 12 months may be granted when the following criterion is met:

    Prostate cancer indication

    • Treatment of prostate cancer

    Salivary Gland Tumor

    Authorization of 12 months may be granted when all of the following criteria are met:

    Salivary gland tumor indication

    • Disease status

      • The tumor is recurrent
      • The tumor is unresectable

    Continuation Therapy

    Prostate Cancer Continuation

    Authorization of 12 months may be granted for reauthorization when all of the following criteria are met:

    Prostate cancer continuation

    • Clinical benefit

      • The member is experiencing clinical benefit to therapySerum testosterone <50 ng/dL (example of clinical benefit)
    • No unacceptable toxicity

      • The member has not experienced unacceptable toxicity

    Salivary Gland Tumor Continuation

    Authorization of 12 months may be granted for reauthorization when all of the following criteria are met:

    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyLeuprolide Mesylate (Camcevi ETM™; Camcevi Kit)
    Policy CodePolicy ID_CHS_47632026_0926
    Change TypeNo material clinical or coverage changes
    Effective DateDec 1, 202612d
    Next Review DateN/A
    Key ActionSubmit androgen receptor (AR)-positive test results when applicable to initiate prior authorization review.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and DocumentationPolicy BackgroundInitial TherapyContinuation Therapy
    Denial Risk

    Indication Outside Covered Uses

    Requests for indications outside the covered FDA-approved or compendial uses are considered experimental/investigational and not medically necessary.

    • Covered compendial uses listed in this policy are salivary gland tumor and prostate cancer.
    • Verify that the requested indication is within a covered use before submitting authorization.
    Denial Risk

    Salivary Gland Tumor Criteria

    For salivary gland tumor, authorization may be granted for up to 12 months only when the disease is recurrent, unresectable, or metastatic and the tumor is androgen receptor positive.

    • Treatment may be requested as a single agent or in combination with abiraterone and prednisone.
    • Document recurrent, unresectable, or metastatic disease and AR-positive tumor status.
    Denial Risk

    Continuation Criteria Not Met

    Reauthorization may be denied when continuation criteria are not met. The member must be experiencing clinical benefit and must not have unacceptable toxicity or disease progression on the current regimen.

    • For prostate cancer, document clinical benefit (for example, serum testosterone less than 50 ng/dL) and absence of unacceptable toxicity.
    • For salivary gland tumor, document no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Authorization for continued treatment may be granted for up to 12 months when the applicable continuation criteria are satisfied.
  1. The tumor is metastatic
  2. Tumor status

    • The tumor is androgen receptor positiveAR-positive
  3. Treatment regimen

    • Treatment is administered as a single agent
    • Treatment is administered in combination with abiraterone and prednisone
  4. Salivary gland tumor continuation

    • No unacceptable toxicity

      • There is no evidence of unacceptable toxicity while on the current regimen
    • No disease progression

      • There is no evidence of disease progression while on the current regimenNo disease progression